Skip to content
On Friday, Novavax started its phase 3 coronavirus trial to test for safety and efficacy of its vaccine. This comes as AstraZeneca received partial immunity with the EU states saying that they will pay for part of the expenses if problems continue to arise with patients. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus....
California’s decision this week to pull the plug on the sale of new gas-powered cars and light trucks by 2035 is raising the ire of the Trump administration....
Yahoo Finance's Akiko Fujita and Sibile Marcellus discuss how Barclays upgraded cruise stocks, boosting the sector, after months of pressure due to the coronavirus....
Having a good credit score is beneficial, and an excellent score is even better. But what if you could achieve the perfect credit score? To attain the highest credit score there is, you'll need to have outstanding credit practices, meet … Continue reading ->The post What Is the Highest Credit Score You Can Have? appeared first on SmartAsset Blog....
Allied Motion Technologies Inc. (NASDAQ:AMOT) shareholders have seen the share price descend 11% over the month. But......
It's been a couple of week now since SVB Leerink analyst Mani Foroohar cited worries about increased competition in the CVOID-19 vaccine race (200 vaccines in process, dozens in clinical trials), and mRNA-1273 lost "lead in clinical development" in deciding to downgrade Moderna (MRNA) stock to "underperform." A couple of weeks later... he's still not optimistic.Foroohar explains that mRNA-1273 still appears like it will prove to be an effective vaccine against coronavirus. The FDA is looking for vaccines to prove 50% "vaccine efficacy" at a minimum before approving them for Emergency Use Authorization (EUA). mRNA-1273 looks likely to clear that bar easily, with efficacy percentages trending to exceed 60%, and perhaps rise as high as 75% or better "in a best case scenario."How soon will we know for sure that mRNA-1273 makes the cut? Trial suspensions such as the one AstraZeneca suffered earlier this month when a patient in one of...
The sell-off in Nikola Corporation (NASDAQ: NKLA) since the Hindenburg Research report accusing the company of being an "intricate fraud built on dozens of lies" took a breather on Friday. Investors must now decide if the fraud allegations and the departure of chairman Trevor Milton is a long-term buying opportunity or if the worst is yet to come for the stock.The Bull Case: Earlier this week, Cowen analyst Jeffrey Osborne defended Nikola. Osborne said investors should understand that the optics of Milton's departure are terrible for the stock in the near term, but the resignation will help minimize distractions in the longer term."We believe Steve Girsky at the helm of the Board and Mark Russell and Kim Brady controlling the communications and narrative from management will set a more measured and less promotional tone with investors," Osborne wrote in a note.Osborne said he has known the Nikola team for nearly three...
